Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line-Reference-Cited by-同舟云学术

Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line

Published:2017-03-31 Issue:2 Volume:46 Page:293-302
ISSN:2169-1401
Container-title:Artificial Cells, Nanomedicine, and Biotechnology
language:en
Short-container-title:Artificial Cells, Nanomedicine, and Biotechnology

Author:

Shali Hajar¹²,Shabani Mahdi³,Pourgholi Fatemeh⁴,Hajivalili Mahsa⁴,Aghebati-Maleki Leili⁴,Jadidi-Niaragh Farhad¹,Baradaran Behzad⁴,Movassaghpour Akbari Ali Akbar⁵,Younesi Vahid⁶⁷,Yousefi Mehdi⁸⁹

Affiliation:

1. Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;

2. Student’s Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;

3. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

4. Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran;

5. Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;

6. Pishtaz Teb Diagnostics, Tehran, Iran;

7. Faculty of Paramedical Sciences, Alborz University of Medical Sciences, Karaj, Iran;

8. Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;

9. Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Funder

Tabriz University of Medical Sciences

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Biomedical Engineering,General Medicine,Medicine (miscellaneous),Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21691401.2017.1307212

Reference41 articles.

1. Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

2. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

4. Lung cancer: Future directions

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chitosan-based smart stimuli-responsive nanoparticles for gene delivery and gene therapy: Recent progresses on cancer therapy;International Journal of Biological Macromolecules;2024-10

2. Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress;Molecular Therapy - Nucleic Acids;2024-09

3. Revolutionizing Lung Cancer Treatment: Nanotechnology-Driven Advances in Targeted Drug Delivery and Novel Therapeutic Strategies;Journal of Drug Delivery Science and Technology;2024-09

4. The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy;Pharmaceutics;2024-07-23

5. Smart Physicochemical-triggered Chitosan-based Nanogels for siRNA Delivery and Gene Therapy: A Focus on Emerging Strategies and Paradigms for Cancer Therapy;Current Medicinal Chemistry;2024-06-05